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Abstract
Background: Since 2011 six immune checkpoint inhibitors (ICI) have been approved to treat patients with many
advanced solid tumor and hematological malignancies to improve their prognosis. Case reports of their endocrine
immune-related adverse events [irAEs]) are increasingly published as more real-world patients with these
malignancies are treated with these drugs. They alert physicians of a drug’s AEs (which may change during a
drug’s life cycle) and contribute to post-marketing safety surveillance. Using a modified framework of Arksey
and O’Malley, we conducted a scoping review of the spectrum and characteristics of ICI-induced endocrinopathies
case reports before and after ICIs are marketed.
Methods: In July 2017, we searched, without date and language restrictions, 4 citation databases for ICI-induced
endocrinopathies. We also hand-searched articles’ references, contents of relevant journals, and ran supplemental
searches to capture recent reports through January 2018. For this study, a case should have information on type of
cancer, type of ICI, clinical presentation, biochemical tests, treatment plus temporal association of ICI initiation with
endocrinopathies. Two endocrinologists independently extracted the data which were then summarized and
categorized.
Results: One hundred seventy nine articles reported 451 cases of ICI-induced endocrinopathies - 222 hypopituitarism,
152 thyroid disorders, 66 diabetes mellitus, 6 primary adrenal insufficiencies, 1 ACTH-dependent Cushing’s syndrome,
1 hypoparathyroidism and 3 diabetes insipidus cases. Their clinical presentations reflect hormone excess or deficiency.
Some were asymptomatic and others life-threatening. One or more endocrine glands could be affected. Polyglandular
endocrinopathies could present simultaneously or in sequence. Many occur within 5 months of therapy initiation; a
few occurred after ICI was stopped. Mostly irreversible, they required long-term hormone replacement. High dose
steroids were used when non-endocrine AEs coexisted or as therapy in adrenal insufficiency. There was variability of
information in the case reports but all met the study criteria to make a diagnosis.
Conclusions: The spectrum of ICI-induced endocrinopathies is wide (5 glands affected) and their presentation varied
(12 endocrinopathies). Clinical reasoning integrating clinical, biochemical and treatment information is needed
to properly diagnose and manage them. Physicians should be vigilant for their occurrence and be able to
diagnose, investigate and manage them appropriately at onset and follow-up.
Keywords: Cancer immunotherapy, Immune checkpoint inhibitors (ICI), ICI-induced endocrinopathies, Endocrine
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Introduction
Advances in our understanding of the immune response
to cancer and mechanisms of immune modulation have
been translated to immunotherapy for the treatment of
many advanced solid tumor and hematological malig-
nancies. The two most promising advances in cancer im-
munotherapy are cell-based adoptive therapy modalities
and immune regulatory modalities. The immune regula-
tory modalities currently have a wider therapeutic utility
than cell-based therapies. They consist of monoclonal
antibodies (mAbs) to proteins known as immune check-
point regulators - cytotoxic T-lymphocyte-associated
antigen-4 (CTLA-4), programmed cell death protein-1
(PD-1) and programmed death ligand 1 and 2 (PD-L1
and PD-L2) [1–6].
PD-1 and CTLA-4 are found on lymphocytes. PD-L1/
L2 are found on many cells, including tumor cells. The
typical function of these checkpoint regulator proteins is
to diminish the immune response to antigen, acting as a
brake on the immune system [1–6]. Monoclonal Abs to
these checkpoint regulator proteins, known as immune
checkpoint inhibitors (ICIs), release the brake that has
been placed on the immune system, allowing the pa-
tients’ immune system to attack cancer cells and certain
healthy tissues. There are currently 6 ICIs approved for
the treatment of many advanced cancers (Table 1).
Use of ICIs brings forth a new toxicity called immune-
related Adverse Events (irAEs) whose mechanisms and
manifestations are quite different from those of cytotoxic
chemotherapy, radiation or molecularly targeted agents.
These irAEs are inflammatory in nature with potential
to affect multiple organ systems. While not occurring in
all patients, they are believed to be an autoimmune
response that results from the blocking of the normal
immune regulatory pathways. Common ICI irAEs in-
clude colitis, hepatitis, pneumonitis, dermatitis and
endocrinopathies.
While non-endocrine irAEs require cessation of im-
munotherapy and usually resolve with immunosuppres-
sive therapy [1–6], endocrine irAEs, if managed
appropriately, do not require cessation of ICIs and are,
for the most part, irreversible and require long term
management [7, 8]. Endocrinologists will often be con-
sulted to co-manage these patients and should be famil-
iar with these endocrine irAEs (called ICI-induced
endocrinopathies in this paper).
A drug’s AE profile may change during its life cycle.
Marketed drugs may have previously unreported AEs in
real world patients because these patients do not have to
meet study entry criteria of clinical trials. In addition,
marketed drugs may have rare AEs which surface when
many more patients are treated with them. In the United
States (US), AEs of marketed drugs are reported by
healthcare providers, patients and others directly or in-
directly to the Food and Drug Administration (FDA).
Healthcare providers may also publish their patient’s
AEs as case reports in medical journals. Such publica-
tions contribute to post-marketing safety surveillance of
drugs and alert clinicians to these possible drug AEs.
A 2016 systematic review of case reports of irAEs re-
lated to CTLA-4 and PD-1 blockade therapy [9] was based
on a literature search done in August 2015, four years
after the approval of anti-CTLA-4 mAB (ipilimumab) in
2011 and a few months after the approval of anti-PD-1
mAbs (nivolumab and pembrolizumab) in 2014. It in-
cluded 84 cases of ICI-induced-endocrinopathies – 79
with ipilimumab, 2 with pembrolizumab and 3 with
nivolumab.
Table 1 Immune checkpoint inhibitors approved by the Food and Drug Administration in USA
Ipilimumab
CTLA-4
Nivolumab
PD-1
Pembrolizumab
PD-1
Atezolizumab
PD-L1
Avelumab
PD-L1
Durvalumab
PD-L1
Malignancy
Melanoma √*(3/2011) √*(12/2014) √*(9/2014)
Non-small cell lung cancer √ (3/2015) √ (10/2015) √ (10/2016)
Renal cell carcinoma √ (11/2015)
Hepatocellular carcinoma √ (9/2017)
Classical Hodgkin’ s lymphoma √ (5/2016) √ (3/2017)
Head & neck squamous cell carcinoma4 √ (11/2017) √ (8/2016)
Urothelial Carcinoma √ (2/2017) √ (5/2017) √*(5/2016) √ (5/2017) √*(5/2017)
Colorectal cancer with high msi/mrd √ (8/2017)
Gastric cancer √ (9/2017)
Solid tumor with high msi/mrd √ (7/2017)
Merkel-cell carcinoma √* (3/2017)
Bladder Cancer √ (04/2017)
*First indication approval date by FDA
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Since that review [9], the profiles of ICI-induced endo-
crinopathies have changed for various reasons: (a) many
more advanced cancer patients have been treated with
ICIs; (b) the ICIs have been marketed longer; (c) more
cancers have been approved for treatment with ICIs; (d)
a new subclass of ICI drugs (anti PDL-1 mAbs) was ap-
proved in 2016/2017; and (e) rare cases of ICI-induced
endocrinopathies have been reported as more patients
are treated with these drugs.
In this paper, we report the findings of a scoping re-
view of ICI-induced endocrinopathies case reports based
on a literature search conducted in July 2017, 6 years
after the approval of ipilimumab, 3 years after the ap-
proval of nivolumab and pembrolizumab, and about a
year after the approval of atezolimumab, avelumab and
durvalumab. We aim to uncover new knowledge of the
changing profiles of ICI-induced endocrinopathies, be-
fore and after marketing, as more real-world patients
with different advanced cancers are treated with these
drugs.
Method
We used the framework proposed by Arksey and O’Malley
[10] and modified by Levac et al. [11] to conduct this scop-
ing review to map out the ICI-induced endocrinopathies.
Stage 1: Identifying the research questions – Purpose
What is the spectrum (extent, range and nature) of
ICI-induced endocrinopathies? How and when did they
present clinically? What investigations were conducted
to support their diagnoses? How were they managed at
onset and what were their outcomes?
Stage 2: Identifying relevant studies- data sources and
searches
In July 2017, we searched 4 citation databases for pub-
lished articles and abstracts of cases of endocrinopathies
associated with ICI therapy for cancer. The search was
initially developed in 3 Ovid MEDLINE databases
(MEDLINE, In-Process & Other Non-Indexed Citations,
Epub Ahead of Print) and then optimized for Embase.
com, Cochrane Central Register of Controlled Trials via
Wiley Online Library, and Clarivate Analytics Web of
Science. The searches were built with a combination of
controlled terms (Medical Subject Headings and
EMTREE when available), and title or abstracts key-
words. No date or language restrictions were included in
the searches, but animal studies, editorials, and com-
ments were excluded from review.
Throughout the review process until January 31, 2018
the authors conducted hand-searches of reference lists
in articles, reviewed the contents of relevant journals,
and ran supplemental searches in Ovid MEDLINE,
Embase, and the Cochrane Central Register to capture
recently published reports. Duplicate citations were ex-
cluded in EndNote X6 (Clarivate Analytics). (All repro-
ducible search strategies are available in Additional file
1: Appendix 1).
Stage 3: Study selection
For eligibility screening, the citations were categorized
by type of endocrinopathy. For this review, a case should
have information on the type of cancer, type of ICI used,
clinical presentation, biochemical tests’ results, imaging
results (if done), and initial and follow-up treatment.
Stage 4: Charting the data – Data extraction
The citations were distributed to teams of at least 2 en-
docrinologists to review (pituitary, adrenal and parathy-
roid, and diabetes insipidus: MHT and LYS; thyroid: RI
and MHT; Diabetes mellitus: KMS, RG and MHT).
Using a 2-step approach, each team member reviewed
the title and abstract to identify potentially eligible rele-
vant citation. Then, the full paper, if available, was re-
trieved, reviewed and data extracted. Non-English
articles were translated with Google Translate.
The reviewers screened all assigned citations inde-
pendently using a standardized data extraction form
(Additional file 2: Appendix 2) to collect data on each
case according to the guidelines for AEs publication as
recommended by the International Society of Pharmaco-
epidemiology and the International Society of Pharma-
covigilance to evaluate the quality of case reports [12].
They then compared their decisions and resolved any
differences by consensus.
Stage 5: Collating, summarizing and reporting the results
For this review, a case should have information on the
type of cancer, type of ICI used, clinical presentation, bio-
chemical tests’ results, imaging results (if done), and initial
and follow-up treatment. When all the above is not re-
ported, the case should have information on 2 of the fol-
lowing: clinical, biochemical and treatment information.
To imply association, there should be close temporal rela-
tionship between ICI therapy initiation and subsequent
development of endocrinopathy. We summarized and cat-
egorized the identified ICI-induced endocrinopathies ac-
cording to the endocrine gland affected, whether it was
associated with hyper- or hypofunction of the gland, and
whether it involved one or more endocrinopathies (poly-
glandular endocrinopathies).
Results
Figure 1 shows the outcomes of the literature search.
Of the 1041 citations identified, 218 had ICI-induced
endocrinopathies citation with cases with sufficient
information for this review. Some of these articles
had information on two or more endocrinopathies.
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Eliminating these duplicates left 179 unique articles
(116 papers, 43 abstracts and 20 letters to editor)
which reported 451 cases of ICI-induced endocrinopa-
thies that met study criteria for diagnosing the case.
Five endocrine glands are affected with 12
endocrinopathies:
 pituitary (hypopituitarism (multiple or isolated
hormone deficiency[ies]), diabetes insipidus, and
ACTH-dependent Cushing’s syndrome);
 thyroid (thyrotoxicosis [Graves’ disease and thyroiditis]
and hypothyroidism [primary hypothyroidism and
thyrotoxicosis progressing to hypothyroidism]),
 adrenal (primary adrenal insufficiency),
 pancreas (type 1 diabetes mellitus (T1DM) and type
2 diabetes mellitus (T2DM)), and
 parathyroid glands (primary hypoparathyroidism)
Hypophysitis/anterior hypopituitarism
Table 2 summarizes the data from the 222 cases of
hypophysitis/anterior hypopituitarism [13–96]. (Details
of each case are in Additional file 3: Appendix 3). Of the
222 cases, 220 met the inclusion criteria; the 2 without
biochemical tests’ results had clinical and treatment
information.
This cohort’s median age was 61 years. Most (65%)
were male (in contrast to mostly females in non-ICI in-
duced autoimmune hypophysitis). The majority (87%)
had melanoma. CTLA-4 and PD-1/PD-L1 mAbs were
used as monotherapy in 200 and 15 patients respectively
with 7 on both. The median onset of clinical presenta-
tion was 12 weeks (range 3–76 weeks) after initiation of
ICI. Symptoms reflected the associated hormone(s) defi-
ciency(ies) with or without the mass-effect of pituitary
enlargement (e.g. headache). In the 176 patients with
Fig. 1 PRISMA flow diagram
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detailed hormone information, 36 had one hormone de-
ficiency, 47 had two, 72 had three, 14 with four and 7
with five. Secondary adrenal deficiency was present in
83%, secondary hypothyroidism in 77%, and secondary
hypogonadism in 53% of patients. Of the 167 patients
with pituitary magnetic resonance imaging (MRI)/com-
puterized tomography (CT) scans, 108 showed enlarged/
enhanced pituitary. Not all patients with enlarged pituit-
ary presented with headaches and not all who presented
with headaches (n = 126) had enlarged pituitary. High
dose steroid was used as initial therapy in 69%, physio-
logical dose steroid in 29% and no steroid in 2% of pa-
tients. When the cases were published, 220 were alive
and 2 diseased (cause of death not stated). Of the 220, 184
were on replacement therapy, 32 had no information on
discharge medications, and 4 on no replacement medica-
tions. During the preapproval and post-marketing periods
there were 18 and 204 (166 in the first 4 years of market-
ing) respectively. There were 9 cases of polyglandular
endocrinopathies involving anterior hypopituitarism - plus
thyroiditis [31, 45, 89], plus primary hypothyroidism [60,
82, 90, 93], plus Graves’ disease and T1DM [76], and plus
T1DM [95].
Thyroid diseases
Table 3 summarizes the data from the 152 cases of
ICI-induced thyroid disorders (Details of each case [31,
60, 76, 80, 82, 90, 97–138] are in Additional file 4:
Appendix 4).
Thyrotoxicosis
Of the 73 thyrotoxicosis cases, 6 had Graves’ disease and
67 had thyroiditis. All had decreased thyroid stimulating
hormone (TSH) and elevated free thyroxine (FT4)/free
triiodothyronine (FT3) in addition to the clinical and
treatment information. Those with Graves’ disease also
had positive thyrotropin receptor Ab (TRAb) or Thyroid
Stimulating Immunoglobulin (TSI). Both groups may or
may not have positive thyroid peroxidase (TPO) and/or
thyroglobulin (TG) Ab. For those who had radioisotope
thyroid scans, Graves’ disease patients had increased up-
take and thyroiditis patients had decreased uptake.
Graves’ disease
This cohort’s median age was 54∙5 years. Four of the 6
patients were male. All had metastatic melanoma. Ipili-
mumab was used in 5/6 patients, 4 as monotherapy and
Table 2 Cases of immune checkpoint inhibitors-induced hypophysitis and anterior pituitary insufficiency
Variable Information
1. Number of Reports 84
2. Cases 222
3. Gender Males = 145; Females = 62; Not reported = 15
4. Age (years) Median = 61; Mean + SD = 60.4 + 11.4; Range = 31–85
5. Pertinent medical history PHxEndoD: Reported = 12; Not reported = 210
FHxEndoD: Reported = 2; Not reported = 220
PHxAutoD: Reported = 4; Not reported = 218
6. Type of cancer Melanoma = 193; Renal cell carcinoma = 6; Prostate carcinoma = 7; non-small
cell lung cancer = 5, lung cancer = 5; papillary thyroid carcinoma =1;
mesothelioma =1; not reported = 4
7. Check point inhibitor
ICI Drug D/C?:
Ipilimumab = 188; Nivolumab = 13; Tremelilumab = 4; CTLA-4 = 8; Atezolizumab
= 2; Ipilimumab + Nivolumab = 3; Nivolumab, then Ipilimumab = 1; Ipilimumab,
then Pembrolizumab = 2; Ipilimumab, then Nivomumab = 1.
Yes = 45 No = 17 Not reported = 160
8. Clinical presentation Reflects the hormone(s) affected
9. Onset (weeks) after first dose Median = 12; Mean = 13.8 + 10.3; Range 3–76
10. Biochemical tests ↓ACTH/cortisol = 183;
↓TSH/FT4/FT3 = 172;
↓LH/FSH/T/Estradiol = 137;
↓PRL = 22; ↓GH/IGF-1 = 22. ↑TSH, ↓FT4,/FT3 = 2
11. Diagnosis (patients with # hormone deficiencies[def]) 5 deficiency (def) = 7; 4 def = 14; 3 def = 72; 2 def = 47;
One (isolated) def = 36 (31 ACTH, 4 TSH, 1 LH, FSH def).
3 reports with case series account for remainder
12. Imaging Brain/Pituitary MRI/CT Enlarged/Enhanced = 108; Normal 49; Not reported =11; Not done = 11; Sella
abnormality = 3; atrophy = 3
3 reports with case series account for remainder
13. CTCAE grade reported Yes = 5; Not reported in 217
14. Therapy at onset at diagnosis High dose steroids = 144; steroids = 62; no steroids = 7; Not reported = 9
15. Outcome 219 recovered/discharged (replacement therapy 195 & 24 not reported); 3 deceased.
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1 with Nivolumab. The median onset of clinical presen-
tation was 7 weeks after initiation of ICI (range = 6–
416). Symptoms ranged from Graves’ eye disease [97,
98] to hyperthyroidism. High dose steroid was used as
initial therapy in 3 cases and anti-thyroid drugs in 4
cases. All improved and 2 were on replacement thyrox-
ine (1 had thyroidectomy and the other became
hypothyroid). Two cases were reported before ipilimu-
mab approval and 3 post-marketing. One case used tre-
melimumab which has not been approved yet. One case
of polyglandular endocrinopathy had Graves’ disease
followed by T1DM and anterior hypopituitarism [76].
Thyroiditis
This cohort’s median age was 61 years. In those with
identified gender, 53% were female. The majority (61%)
had metastatic melanoma. Anti-PD-1 mAbs were used
in 60/67 patients, monotherapy in 44 and with/after Ipi-
limumab in 8 and 8 respectively. The median onset of
symptoms was 6 weeks after initiation of ICI (range = 3–
28). Clinical presentation ranged from no symptoms to
thyroid storm [105, 106, 110]. High dose steroid was
used as initial therapy in 6 patients (2 of these cases had
concomitant adrenal insufficiency), anti-thyroid drugs in
6, β-blockers in 15 and iodide solution in 3. Of the 67
patients with follow-up information, 46 needed thyrox-
ine replacement. During the pre-approval and post-mar-
keting periods there were 2 and 65 reported respectively.
There were 7 cases of polyglandular endocrinopathies
involving thyroiditis - plus anterior hypopituitarism [31,
123, 126]; plus primary adrenal insufficiency [126]; plus
pituitary adrenocorticotrophic hormone (ACTH)-
dependent Cushing’s syndrome and anterior hypopituit-
arism [127]; plus hypoparathyroidism [122]; and plus
type 1 diabetes mellitus [128, 130].
Hypothyroidism
Of the 79 cases of hypothyroidism, 29 had primary
hypothyroidism and 50 had hypothyroidism preceded by
transient hyperthyroidism. Primary hypothyroidism cases
had elevated TSH and decreased FT4/FT3. In those with
hyperthyroidism progressing to hypothyroidism, TSH
(when reported) was high in 19 cases. The remaining 31
were stated to have hypothyroidism with clinical and/or
treatment information.
Primary hypothyroidism
This cohort’s median age was 64 years. In those with iden-
tified gender, 52% were male. Sixty-two percent had meta-
static melanoma. As monotherapy anti-PD-1/PDL-1
mAbs were used in 16; with ipilimumab 11 (in sequence
in 9 and combined 2) and ipilimumab monotherapy 2.
The median onset of symptoms was 12 weeks after ICI
initiation (range = 7–36). Symptoms ranged from mild to
severe myxedema coma [133]. Levothyroxine (LT4) was
started in 26, no LT4 in 1 and 2 not reported. Steroids
were used as initial therapy in 3 because of concomitant
adrenal insufficiency and insulin was used in 2 to treat
diabetes mellitus. In follow-up, 23 needed LT4 re-
placement, 5 not reported, and I died (cause un-
known). During the pre-approval and post-marketing
periods 1 and 28 cases were reported respectively.
There were 6 cases of polyglandular endocrinopathies
involving primary hypothyroidism - plus anterior
hypopituitarism [60, 82, 90, 93] and plus diabetes
mellitus [132, 134].
Thyrotoxicosis progressing to hypothyroidism
This cohort’s median age was 63 years. In those with
identified gender, 56% were male. The majority (59%)
had melanoma. Anti-PD-1/ PDL-1 mAbs were used in
48 patients - monotherapy in 36, after ipilimumab in 5
and in combination with ipilimumab in 7. The median
onset of symptoms was 6 weeks after hyperthyroidism
(range 3–15). Many patients were stated to be
hypothyroid without clinical information on symptoms.
At onset of symptoms 39 patients were prescribed LT4.
In follow-up, 44 needed LT4 replacement, and LT4 re-
placement was not reported in 6 patients. All 50 cases
were reported in post-marketing period. There were 7
cases of polyglandular endocrinopathies involving hyper-
thyroidism progressing to hypothyroidism - plus anterior
hypopituitarism [76, 123];plus primary adrenal insuffi-
ciency (PAI) [126]; plus pituitary ACTH-dependent
Cushing’s syndrome [127]; plus hypoparathyroidism
[122]; and plus T1DM [76, 128].
Diabetes mellitus
Table 4 summarizes the data from the 66 cases of
ICI-induced diabetes mellitus. (Details of each case [76,
127, 128, 130, 139–185] are in Additional file 5:
Appendix 5). All met the inclusion criteria.
Diagnosis of T1DM was based on clinical (onset, clinical
symptoms, immediate and subsequent insulin therapy)
and biochemical (glucose, ketone bodies, islet antibodies,
acidotic state) data. Any case with positive islet antibo-
dy(ies) is diagnosed as T1DM based on the presumed
underlying autoimmune nature. In cases where islet anti-
bodies were negative or not reported, we diagnosed them
to have T1DM based on their presentation with diabetic
ketoacidosis (DKA) in a previously normoglycemic pa-
tient, new onset severe hyperglycemia with a low
C-peptide in a patient without known diabetes, new insu-
lin requirement in a patient with known T2DM; and any-
one with “fulminant” T1DM.
This cohort’s median age was 63 years. Most (64%)
were male and the majority (45%) had metastatic
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melanoma. The ICIs used were anti-PD-I mAbs (n =
45); anti-PD-L1 mAbs (n = 5); anti- PD-1 mAbs +
anti-CTLA-4 mAb (n = 7); anti-CTLA-4 mAb then
Anti-PD-1 mAbs (n = 8); anti CTLA-4 mAb (n = 1).
The median onset of clinical presentation was 7.5 weeks
after initiation of ICI (range = 1–52 weeks). Sixty-five
had T1DM based on our diagnostic criteria (see above)
and one probably had T2DM (had duodenopancreatect-
omy and did not require insulin to treat mild hypergly-
cemia) [178]. There were 4 cases with T2DM before ICI
therapy and who developed T1DM based on a new insu-
lin requirement when on ICI [132, 149, 171].
In the T1DM cohort, 43 presented in DKA and 20
with marked hyperglycemia. In the DKA group 12,
mostly from Japan, were described to have fulminant
T1DM [130, 139, 147, 148, 152–157, 165, 168–170].
Islet-related Abs (Glutamic acid decarboxylase 65(GAD
65), Islet Antigen 2 (IA2), Insulin auto-antibody (IAA)
or Zinc Transporter 8 (ZnT8) Ab were positive in 51.5%
(n = 34), negative in 41% (n = 27) and not reported in
7.5% (n = 5). At onset of clinical presentation, high dose
steroid was used in 10, cases, insulin infusion in 60, oral
glucose-lowering medications initially continued in 4,
with 2 no information on treatment. All 66 patients re-
covered from their hyperglycemia with treatment - 53
remained insulin dependent and the outcomes of 13
were not reported. One patient, initially requiring insu-
lin, discontinued insulin on day 81 after pembrolizu-
mab was discontinued [142]. All the cases using
anti-PD-1 mAbs were reported post-marketing, most
2–3 years after their approval in 2014. There were 6
cases of polyglandular endocrinopathies involving
T1DM - plus anterior hypopituitarism [75, 95], plus
anterior hypopituitarism + Graves’ disease [76], plus,
thyroiditis [129, 130], plus primary hypothyroidism
[132], and plus hyperthyroidism progressing to
hypothyroidism [76, 130].
Primary adrenal insufficiency, ACTH-dependent Cushing’s
syndrome, hypoparathyroidism, and diabetes insipidus
Table 5 summarizes the data from 6 cases of PAI, 1 of pitu-
itary ACTH-dependent Cushing’s syndrome, 1 of primary
hypoparathyroidism and 3 of diabetes insipidus following
ICI therapy. (Details of cases [16, 19, 34, 41, 122, 126, 127,
186–189] are in Additional file 6: Appendix 6). All met the
criteria for inclusion in this review.
Table 4 Cases of Immune Checkpoint Inhibitors Induced Diabetes Mellitus
Variable Information
Reports 55
Cases 66
Gender Males = 42; Females = 24
Age (years) Median = 63.5; Mean ± SD = 62 ± 13.2; Range = 28–84
Pertinent medical history PHx diabetes: Reported = 36; Not reported = 30
FHx diabetes: Reported 27; Not reported = 39
Hx AutoD: Reported = 15; Not reported = 51
Type of cancer (all metastatic) Melanoma = 30; Non-small cell lung cancer = 10; Renal cell carcinoma = 7;
Lung cancer = 11; Urothelial carcinoma = 2, Small cell jaw cancer = 1, Small
cell tonsillar cancer = 1; Small cell maxillary sinus cancer = 1; Hodgkin’s
lymphoma = 1, Cholangiocarcinoma = 1, Not reported = 1
Check point inhibitor
Drug D/C?:
Pembro = 13; Nivo = 32; Nivo + Ipi = 6; Pembro + Ipi = 1; Ipi, then Pembro = 5;
Ipi, then Nivo = 3; Avelu + Utomi = 1; Atezo = 2; Unnamed PDL-1 = 2; Ipi = 1
Yes = 22, No = 15, Ipi stopped/Pembro continued = 1, Not reported = 28
Clinical presentation DKA = 43; Hyperglycemia = 20; Not reported = 3
Onset (weeks) after first dose Median = 7, Mean ± SD = 11.7 ± 11.7 Range 1–52
Biochemical tests ↑Glucose = 57; ↑A1c = 49; ↑β-OHB = 10
↓pH = 35; ↓C-pep = 48
Antibody evaluation Any antibodies (GAD65, IA2, ZnT8, IAA) positive = 34 (51.5%)
Antibodies negative = 27 (41%)
Antibodies not reported = 5 (7.5%)
Pancreatic imaging CT with ↓ volume or atrophy = 3, CT with pancreatitis = 1; MRI with diffuse
inflammation = 1
CTCAE severity grade reported Yes = 4; Not reported = 62
Therapy at onset at diagnosis in addition to insulin Metformin =1, Glimepiride = 1,glyburide = 1; Diet = 2, High dose steroids* = 10
Outcome Remained insulin-dependent = 52, Recovered = 1,
Not reported = 13
*Treatment dose steroids as part of chemotherapy regimen (n = 2), treatment of other autoimmune manifestation (n = 3), to reverse autoimmune diabetes (n =
2), to decrease insulin resistance (n = 1); for adrenal insufficiency (n = 2)
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Primary adrenal insufficiency [16, 34, 126, 186–188]
This cohort’s median age was 52 years. In those with
identified gender, 60% were male. Of the 6 patients, 3
had metastatic melanoma. Anti-PD-1 mAbs were used
in 4/6 patients as monotherapy. Ipilimumab was used in
2 patients. The median onset of symptoms was 10 weeks
after ICI initiation (range = 1.5–36). High dose steroid
was used as initial therapy in 4 and physiological steroids
in 2 cases. All recovered clinically with treatment and
were on replacement oral hydrocortisone with two [126,
186] also on fludrocortisone. The patient reported in
[188] received iv prednisolone which contains some
mineralocorticoid effect but at discharge fludrocorti-
sones was not mentioned. One case [34] initially had
secondary adrenal insufficiency (SAI) but was found to
have enlarged adrenals at week 16 after ipilimumab initi-
ation. When a cosyntropin stimulation test done then
showed no cortisol response the authors concluded the
patient also had PAI. A negative CST occurs in PAI but
can also occur with SAI of significant duration.
Pituitary ACTH-dependent Cushing’s syndrome [127]
Onset of the hypercortisolism symptoms was 12 weeks
after initiation of ipilimumab plus nivolumab for melan-
oma. Four weeks later, secondary adrenal insufficiency
developed. Both these were preceded by transient hyper-
thyroidism in week 6 that progressed to secondary
hypothyroidism in week 9 after the first dose of ICI.
Primary hypoparathyroidism [122]
This melanoma patient, treated with ipilimumab plus
nivolumab, developed symptoms of acute hypocalcemia
6 weeks after the first dose of ICIs. On the 3rd day in
hospital, he developed transient thyroiditis which pro-
gressed to hypothyroidism.
Diabetes insipidus (DI) [19, 41, 189]
Two patients were treated with ipilimumab and 1 with
avelumab (the first case of DI following anti-PD-L1 ther-
apy). The median onset of symptoms (polydipsia and poly-
uria with euglycemia) was 12 weeks after initiation of ICI.
Two [41, 189] reported biochemical data in keeping with
DI and these 2 were discharged on desmopressin.
Reported endocrinopathies not supported by data
Two cases of hyponatremia were attributed to syndrome
of inappropriate ADH secretion [22, 186]. However, both
had secondary adrenal insufficiency that could have
caused the hyponatremia.
The only case of hypercalcemia was associated with in-
creased PTH-related peptide, not PTH; hence, it was not
primary hyperparathyroidism [189].
Discussion
Clinical presentations
Compared with the 2016 systematic review of case reports
of irAEs, which included 84 cases of endocrine irAEs, in
ICI treated cancer patients [9], our review shows a
five-fold increase in case reports of endocrine irAEs (from
84 to 451). This increase most likely reflects wider use of
ICI therapy in more cancer patients - (a) more melanoma
patients (the original indication) are now treated with 2
classes of ICIs; (b) as new indications are approved for
other cancers, more patients are now treated with ICIs
(Table 1); and (c) more cases of anti-PD-1-induced endo-
crinopathies were reported in the past 3 years after their
approval in 2014 (Fig. 2). During the 3–4-years period
after approval of each class of ICI (ipilimumab in 2011
and nivolumab and pembrolizumab in 2014) a striking in-
crease in cases of ICI-induced endocrinopathies were pub-
lished with their use in the first 2–3 years post-marketing
period (Fig. 2). With the introduction of anti-PD-L1 drugs
in 2016 and 2017 for cancer patients, more cases
ICI-induced endocrinopathies [190] will likely be reported
in the coming 3–4 years.
In the 2016 review [9] ipilimumab was associated with
68 cases of hypophysitis, 4 cases of thyrotoxicosis, 4 cases
of hypothyroidism, 1 case of syndrome of inappropriate
secretion of antidiuretic hormone, 1 case of central
adrenal insufficiency, 1 case of primary adrenal insuffi-
ciency; pembrolizumab was associated with 1 case of
hypothyroidism and 1 case of diabetes mellitus; and nivo-
lumab was associated with 2 cases of hypothyroidism. Our
scoping study uncovers a wider spectrum of ICI-induced
endocrinopathies - 222 hypopituitarism, 152 thyroid disor-
ders, 66 diabetes mellitus, 6 primary adrenal insufficiency,
1 pituitary ACTH-dependent Cushing’s syndrome, 1
hypoparathyroidism and 3 diabetes insipidus cases (Fig. 3).
Clinically, endocrinopathies can present with symptoms
of hormone deficiency, hormone excess or both (in the
same or different glands). The spectrum of clinical presen-
tation ranges from no symptoms [93, 111, 112, 116, 118,
135] (diagnosis made by biochemical tests) to severe,
life-threatening symptoms - thyroid storm [105], myx-
edema coma [133] and diabetic ketoacidosis [144]. When
symptomatic, the presentations of these ICI-induced
endocrinopathies reflect the perturbations of hormone(s)
produced by the affected gland(s).
Single hormone deficiency - ACTH in isolated ACTH
deficiency [34, 45, 70, 86] or insulin in T1DM [132, 139,
140, 142]) are more commonly reported than single hor-
mone excess - thyroxine in Graves’ disease [102] and
ACTH in Cushing’s syndrome [127]. Occasionally, the
endocrinopathy may present with symptoms of one hor-
mone excess followed by symptoms that reflect the same
hormone’s deficiency - hyperthyroidism progressing to
hypothyroidism [116].
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Multiple glands may be affected presenting as polygland-
ular endocrinopathies. The patient can present with symp-
toms and biochemical changes of two endocrine glands in
sequence - thyroiditis and type 1 diabetes mellitus [130],
hypoparathyroidism and thyroiditis [122], thyroiditis and
ACTH-dependent Cushing’s syndrome [127], and primary
hypothyroidism and isolated ACTH deficiency [93].
When the pituitary gland, which secretes 7 hormones,
is affected, multiple hormonal deficiencies can occur
simultaneously; then, the patient presents with symp-
toms of multiple pituitary hormones deficiencies [14]. In
our review, various combinations of pituitary hormone
deficiencies occurred, with 3 hormone deficiencies being
the commonest. Finally, patients with hypophysitis are
sick and their thyroid/gonadal axis may be suppressed in
the acute phase of the disease.
Onset of symptoms can occur as early as 1 week [140]
or as late as 416 weeks [102] with most in the first 20
weeks.
The pituitary ACTH-dependent Cushing’s syndrome
[127] is the first case reported and needs to be con-
firmed. The etiology of the increased ACTH secretion
may be due to ectopic Corticotropin-Releasing Hormone
(CRH) production as expression of CRH has been re-
ported in advanced melanoma cells [191] and Cushing’s
syndrome due to ectopic CRH secretion has been re-
ported [192]. As this case report’s authors did not inves-
tigate this, we cannot comment further but raised this as
a possible etiology and point out that this patient’s Cush-
ing’s syndrome and hypophysitis are unlikely to be re-
lated. Whether and how the ICIs stimulate the secretion
of CRH remains to be reported.
High-dose systemic glucocorticoids are given as im-
munosuppressive to treat concomitant non-endocrine
irABs (colitis, hepatitis, etc). For endocrine irABs,
high-dose systemic glucocorticoids are given to treat ad-
renal crisis, hypophysitis and in selected cases of thy-
roiditis. Such treatment did not improve the outcome of
Fig. 2 Reported cases of immune checkpoint inhibitor-induced endocrinopathies are increasing
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ipilimumab-related hypophysitis in melanoma patients
[8]. Recently, high-dose glucocorticoids treatment for
ipilimumab-related hypophysitis in melanoma patients
was associated with reduced survival [193]. High dose
systemic glucocorticoids when given to diabetes patients
(see Table 4) can worsen their hyperglycemia.
Subclass of ICI and ICI-induced endocrinopathies
We found anti-CTLA-4 mAb to be the ICI most fre-
quently associated with hypophysitis and anterior pituit-
ary hormone(s) deficiencies (n = 188 as monotherapy)
compared with Anti-PD-1 mAbs (n = 13). The differ-
ences observed above may reflect longer period of use as
ipilimumab was approved in 2011, 3 years before nivolu-
mab and pembrolizumab. Other reasons, including biol-
ogy of endocrine glands, may explain this difference (see
below).
We found anti-PD-1 mAbs are the ICIs more often as-
sociated (when compared with CTLA-4 Ab) with auto-
immune thyroiditis (37 vs 6 as monotherapy), primary
hypothyroidism (15 vs 2 as monotherapy), hyperthyroid-
ism progressing to hypothyroidism (30 vs 2 as monother-
apy) and type 1 diabetes mellitus (45 vs 1 as
monotherapy). Of note, in our review, all 6 patients with
Graves’ disease were treated with anti-CTLA-4 mAb (5 as
monotherapy). A meta-analysis reported polymorphism of
CTLA-4 can increase the risk for Graves’ disease [194]
but how this interacts with ICI is unclear.
It is improper to calculate the frequency of each
ICI-induced endocrinopathies in this review as we do not
have the total number of cases that have been reported
other than those that have been published. Cukier et al.
reported frequencies of endocrine irAEs observed with
immunotherapies [195]. Relevant to this review, the fre-
quencies for endocrine irAEs for ipilimumab, nivolumab
and pembrolizumab respectively are: hypophysitis 1.5–17,
0.6–1.5 and 0.6–1%; hypothyroidism 1.5–6.8, 9–10.8 and
7–9.1%; hyperthyroidism 4, 2.7 and 3.4–7.8%; primary ad-
renal insufficiency 0.8–1.6, 1% and not reported; Type 1
diabetes not reported, 0.9, and 0.2%. There are similarities
in the frequencies of endocrinopathies associated with dif-
ferent ICIs reported by Cukier et al. [195] and those re-
ported in this review.
Pathogenesis
How ICIs damage endocrine glands are unclear; how-
ever, several hypotheses to explain this have emerged
[196]. All endocrinopathies associated with ICI therapy
are hypothesized to be autoimmune in etiology. Check-
point regulator proteins diminish the immune response
to antigen and hence act as a brake on the immune sys-
tem [1–6]. Blockade of these checkpoint regulator pro-
teins releases this brake and allows the patient’s immune
Fig. 3 Spectrum of immune checkpoint inhibitor-induced endocrinopathies
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system to attack cancer cells as well as damage certain
healthy tissues by autoimmune mechanisms (Fig. 4).
For hypophysitis, a mouse model of anti-CLTA-4-in-
duced hypophysitis demonstrated that CTLA-4 is
expressed in pituitary endocrine cells and, when blocked
by administration of anti-CTLA-4 mAb, leads to
site-specific deposition of complement components, pi-
tuitary infiltration and pituitary Ab formation. This
study also evaluated patients with prostate cancer and
melanoma treated with ipilimumab and showed that
those who developed hypophysitis developed pituitary
Abs that were not seen in the patients who did not de-
velop hypophysitis [47]. CTLA-4 antigen expressed by
pituitary endocrine glands in cancer patients treated
with CTLA-4 blockade was also reported by Caturegli et
al. [63].
Hypophysitis is less common among patients treated
with anti-PD-1/PD-L1 drugs. Some have hypothesized
this is because mAbs to nivolumab and pembrolizu-
mab are in the immunoglobulin (IgG) 4 class [197],
as opposed to ipilimumab, a CTLA-4 antibody of the
IgG1 class, which can activate the classical comple-
ment pathway [47].
The mechanism behind anti-PD-1 induced thyroid
dysfunction is unclear. However, the development of
anti-thyroid antibodies after the initiation of anti-PD-1
therapy suggests these drugs may be modulating the
autoimmune equilibrium and unmasking latent
autoimmunity [119]. As many cases of ICI-induced
hypothyroidism are preceded by a period of transient
hyperthyroidism, the mechanism may be destructive thy-
roiditis with release of thyroid antigen and consequent
secondary antibody production [111]. In our study’s thy-
roiditis cohort, of the 49 patients tested for TPO/TG
Ab, only 18 had positive titers. In addition, in one
patient the hypothyroidism was preceded by Graves’s
disease [76].
In our study, in those autoimmune diabetes patients
who were tested for islet-related Abs (GAD65, IA2,
ZnT8, IAA) 51.5% had positive titers, 41% had negative
titers and 7.5% not reported. Insulin deficiency with low
C-peptide was noted in over 70% patients. Several case
reports [130, 147, 148, 152, 176, 177] of autoimmune
diabetes following ICI therapy reported the HLA type of
their patients increased their risk for developing type 1
diabetes.
Fig. 4 Mechanisms of Action of Anti-PD(L)1 and CTLA-4 Drugs. 1a Normal activation state of T cells after interaction with Antigen presenting cell
(APC). TCR = T-Cell receptor. 1b Inhibition of T cell activation due to CTLA-4 out-competing CD28 for interaction with CD 80/86. 1c Anti-CTLA-4
drug inhibits CTLA-4 thus CD28 is able to interact with CD80/86 and activate T cell. 2a PD-L1 on tumor cell prevents T cell activation. 2b PD-L1 is
blocked by anti-PD(L)1 drugs, T cell activation against tumor is possible
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Many cases of diabetes following ICI therapy were
reported in 2016 and 2017, after the anti-PD-1 drugs
were approved in 2014. Prior to this, T1DM following
ICI therapy was reported to be rare – (a) diabetes
was not reported in a 2016 meta-analysis [198] (b) re-
ported as 0.2–0.9% after anti-PD-1 and 0.1–0.3% after
anti-PD-L1 therapy in 2017 [195], and (c) only 13
cases (0.2%) in the 2018 systematic review and
meta-analysis [199]. Our study identified 65 case re-
ports of T1DM, many more than identified in
meta-analysis of clinical trials [199]. In our study, 12
T1DM cases were fulminant T1DM - acute, recent
onset of severe hyperglycemia with ketoacidosis with
negative islet-related Abs in general [200]. Recently
Stamatouli et al. reported that insulin-dependent dia-
betes induced with checkpoint inhibitors have similar-
ities and differences when compared with classic
T1DM [201].
Case documentation
Very few case reports in our review specified the se-
verity of the endocrine irABs considered “required”
when reporting adverse events [12]. However, based
on the information in the case reports, most were
Grade 2 or 3 with a few Grade 4 cases. Grading the
severity of endocrinopathies can be helpful as some
endocrine irABs are emergencies – DKA, adrenal cri-
sis, thyroid storm and myxedema coma – and can be
life threatening requiring urgent care. Similarly, the
information on the personal and family history of the
specific endocrine disorder or autoimmune disorder is
sparse except for the DM cases. Finally, only 91/445
cases reported stopping the ICI drugs when the irAE
occurred with insufficient information on whether
they were transient or permanent. Of great interest is
1 patient with T1DM did not need insulin 81 days
after pembrolizumab was discontinued [144].
Limitations and strengths
This scoping review has limitations. The first is the
variability of information in published case reports.
Some did not have all the data identified as “re-
quired” or “highly desirable” [12] but had enough to
meet the study criteria. There was variability in the
diagnostic tests done, including their timing. In the
hypophysitis cases the pituitary imaging may be de-
layed and not all had pre-treatment imaging for com-
parison. Secondly, although almost all had close
temporal relationship, there were a few irAEs which
occurred much later [45, 56, 94, 102, 144, 147].
Thirdly, although many cases reported were in full
papers, 43 were abstracts as their full reports could
not be located at the time of writing. Fourthly, our
scoping study covered only published case reports
mainly in post-marketing. Fifthly, our scoping review
included case reports up to January 31, 2018. Since
then other case reports have been published [193]. Fi-
nally, as pointed out in a systematic review [202],
some reports on irAEs in clinical trials, as in our re-
view, do not have all required information.
Our review has strengths: (a) It is comprehensive with
data collected in a standardized way from before and
after marketing published case reports and can uncover
important irAEs not previously addressed. A 2018
meta-analysis [199] addressed only hypothyroidism,
hyperthyroidism, hypophysitis, primary adrenal insuffi-
ciency and diabetes mellitus. (b) Using clinical reason-
ing, diagnoses were based on integrated clinical,
biochemical and management documentation comple-
mented by a temporal relationship between initiation of
ICI and development of endocrinopathies [203]; (c) our
study uncovered many more cases of ICI-induced
T1DM than in a 2016 systematic review of irAEs case
reports [9] and a 2018 meta-analysis of clinical trials
data [199]; and (d) we report unique or first of a kind
endocrinopathy [122, 127] not mentioned in prior sys-
tematic reviews and meta-analysis [199].
Conclusion
In closing, this scoping review mapped the changing
landscapes of ICI-induced endocrinopathies before
and after marketing of 1 anti-CTL4–1 mAb (approved
2011), 2 anti-PD-1 mAbs (approved 2014) and 3
anti-PDL-1 mAbs (approved 2016/2017). In mostly
real-world patients, we uncovered a spectrum of
endocrinopathies – in 5 glands with 12 endocrinopa-
thies that manifest with symptoms of hormone excess
or deficiency.
Case reports can alert physicians of a drug’s AEs [12].
With increasing use of ICIs, physicians in many medical
specialties (oncology, endocrinology, emergency medi-
cine and primary care) should be vigilant for these
ICI-induced endocrinopathies’ occurrence and be able to
diagnose and treat them. “Cross talk” for collaborative
care between oncologists and endocrinologists has been
proposed [204]. It is beyond the scope of this paper to
cover algorithms and guidelines for the diagnosis and
management of ICI-induced endocrinopathies in cancer
patients. Some oncology centers [205, 206], National
Oncology Societies [207, 208] and Society of Endocrin-
ology Emergency Guidance document [209] have pub-
lished algorithms and clinical practice guidelines. The
reporting of endocrine irAEs can be improved [12, 202].
Our findings can help physicians manage their patients
and professional societies develop their clinical practice
guidelines.
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